Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-522 + Docetaxel in Metastatic AIPC
NCT00072930Phase 2Completed
- Sponsor
- MedImmune
- Start
- Dec 2003
- Primary completion
- Apr 2007
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of etaracizumab in prostate cancer (PCa) (2 arms), sponsored by MedImmune. Primary endpoints: Time to disease progression, PSA Response Rate and 1 more. Started Dec 2003; status: completed.
02
Drugs
etaracizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00072930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072930.